There are 2789 resources available
1000P - Screening cancer immunotherapeutic agents using high content imaging and analysis of immune-competent 3D InSight tumor models
Presenter: Francesca Chiovaro
Session: ePoster Display
Resources:
Abstract
1001P - A radiomics model for effective prediction of the treatment benefits of programmed cell death 1 inhibitors in advanced gastric cancer
Presenter: Ai Huang
Session: ePoster Display
1002P - Impact of pharmacodynamic biomarkers in phase I immune-oncology trials
Presenter: Abdulazeez Salawu
Session: ePoster Display
1003P - Expression by immunohistochemistry of p53 tumor suppressor protein as a predictive biomarker of response to immune checkpoint inhibitors in non-small cell lung cancer
Presenter: Alejandro Olivares Hernandez
Session: ePoster Display
1004P - Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability
Presenter: Michael J. Overman
Session: ePoster Display
1005P - A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity
Presenter: Yuji Mishima
Session: ePoster Display
1006P - ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 3+ tumors
Presenter: Sarina Piha-Paul
Session: ePoster Display
1007P - T-cells transgenic for a highly potent PRAME-specific TCR and a chimeric PD1-41BB co-stimulatory receptor represent a promising approach for the treatment of solid tumors
Presenter: Maja Bürdek
Session: ePoster Display
1008P - cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility
Presenter: Mithun Khattar
Session: ePoster Display
1027TiP - A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer
Presenter: Erkut Borazanci
Session: ePoster Display